AMRX Q2 Deep Dive: Diversified Product Mix and Biosimilars Strategy Shape Guidance
Amneal (NASDAQ:AMRX) Beats Expectations in Strong Q2 CY2026, Stock Jumps 15.9%
– Q2 2026 Net Revenue of $796 million ; GAAP Net Income of $58 million ; Diluted Income per Share of $0.18 – – Adjusted EBITDA of $206 million ; Adjusted Diluted EPS of...
Barchart Research What to Expect from AMRX Earnings AMRX Generated July 29, 2026 Current Price $19.10 EPS Estimate $$0.24 Consensus Rating Strong Buy Average Move 3.30% Amneal's Biosimilar Bet Gets Its...
Amneal (AMRX) Reports Q2: Everything You Need To Know Ahead Of Earnings
Spotting Winners: Amneal (NASDAQ:AMRX) And Generic Pharmaceuticals Stocks In Q1
Kaskela Law is investigating Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal”) on behalf of the company’s current shareholders. The investigation seeks to determine whether...
Approval of iohexol injection 350 mg iodine/mL in 50 mL, 75 mL and 100 mL vials, and 300 mg iodine/mL in 50 mL vial, significantly expands Amneal’s injectable contrast portfolio Portfolio now positioned...
3 Reasons AMRX is Risky and 1 Stock to Buy Instead